VCYTVeracyte, Inc.

Healthcare

$45.23+33% 1Y

$45.23

$30.0152 weeks$59.55

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.

1 good, 1 to watch, 1 without data

What the price assumes~+10% a yearderived · Jun 30, 2026

Priced for ~10% a year FCF growth. The price demands less than its three-year revenue growth of 20% a year, expectations look modest.

Vs sector (EV/EBIT)74.6×derived · Dec 31, 2025

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 72% of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What VCYT's price assumes

Veracyte, Inc. trades at 32.3× earnings against 35.2× for the median Diagnostics & Research name, cheaper than its own group.

32.3

Trailing P/E · Diagnostics & Research median 35.2 · cheaper than the typical name in its group

Price / sales: 9.03
Price / sales · today's price, fiscal year to Dec 31, 2025
Free cash flow yield: 3.5%
Free cash flow yield · Diagnostics & Research median 3.7%
Growth the price implies: +10%
Growth the price implies · The price pays for +10% free cash flow growth a year for a decade; the business has delivered +93% a year over the last three.